Protalix Biotherapeutics Inc (PLX)
R&D Expenses
$19.88M
TTM · Period ending: · USD
PLX R&D Expenses
Latest reported$19.88Mperiod ending
Latest reported$19.88Mperiod ending
PLX TTM R&D Expenses ($0.00 → $19.88M)
TTM R&D Expenses
High-resolution chart · PNG
PLX r&d expenses history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | R&D Expenses (USD) |
|---|---|
| 19,879,000 | |
| 21,520,000 | |
| 19,569,000 | |
| 18,057,999 | |
| 16,588,999 | |
| 13,557,999 | |
| 12,969,999 | |
| 11,948,000 | |
| 12,619,000 | |
| 14,133,000 | |
| 17,093,000 | |
| 19,608,000 | |
| 23,325,000 | |
| 26,429,000 | |
| 29,349,000 | |
| 31,373,000 | |
| 31,269,000 | |
| 31,379,000 | |
| 29,734,000 | |
| 33,046,000 | |
| 33,452,000 | |
| 34,949,000 | |
| 38,167,000 | |
| 36,809,000 | |
| 39,121,000 | |
| 43,258,000 | |
| 44,616,000 | |
| 44,990,000 | |
| 45,061,000 | |
| 38,979,000 | |
| 33,724,000 | |
| 32,745,000 | |
| 29,063,000 | |
| 30,648,000 | |
| 28,834,000 | |
| 25,552,000 | |
| 24,219,000 | |
| 23,212,000 | |
| 24,608,000 | |
| 26,598,000 | |
| 26,802,000 | |
| 25,454,000 | |
| 26,191,000 | |
| 23,009,000 | |
| 23,854,000 | |
| 22,345,000 | |
| 21,650,000 | |
| 24,532,000 | |
| 24,064,000 | |
| 25,560,000 | |
| 24,816,000 | |
| 25,307,000 | |
| 26,033,000 | |
| 28,430,000 | |
| 29,951,000 | |
| 29,597,000 | |
| 31,152,000 | |
| 29,616,000 | |
| 31,043,000 | |
| 33,067,000 | |
| 28,695,000 | |
| 31,402,000 | |
| 30,479,000 | |
| 29,451,000 | |
| 30,516,000 | |
| 25,192,000 | |
| 21,638,000 | |
| 17,935,000 | |
| 18,728,000 | |
| 16,908,000 | |
| 17,401,000 | |
| 17,363,000 | |
| 15,404,000 | |
| 15,354,000 | |
| 12,861,000 | |
| 11,844,000 | |
| 8,399,000 | |
| 5,567,000 | |
| 3,773,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |